More information: Komal L. Jhaveri et al, Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer, New England Journal of Medicine (2025). DOI: 10.1056/NEJMoa2501796 Journal ...

This could make KRAS-mutated colon cancer more treatable than previously thought. Our results show that EGFR, a receptor on the cell surface of many cells, also plays an active role in KRAS ...

Credit: Getty Images Repose Gray by Sherwin-Williams and Revere Pewter by Benjamin Moore are two of the most popular neutral shades. They are best sellers from both brands and loved by designers ...

A first-line regimen combining encorafenib, cetuximab, and mFOLFOX6 significantly increases progression-free survival (12.8 vs. 7.1 months) and overall survival (30.3 vs. 15.1 months) compared to ...

Impact of standard vs reduced dosing of sotorasib on efficacy and toxicity in KRAS G12C–mutated advanced non-small cell lung cancer: A systematic review and meta-analysis. This is an ASCO Meeting ...

OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) monotherapy vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and ...

The addition of olaparib to neoadjuvant chemotherapy improved overall survival in BRCA-mutated breast cancer, despite no improvement in pathologic response. Adding the PARP inhibitor led to a 3 ...

The results from Phase Ib/II KYLIN-1 study (NCT06343064) showed that Vebreltinib plus Andamertinib demonstrated notable efficacy and manageable safety in EGFR-mutated NSCLC patients with MET ...

Jill Feldman, cofounder and president, EGFR Resisters, shares the importance of being proactive in managing dermatologic toxicities in epidermal growth factor receptor (EGFR)–positive lung cancer.

First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated ...